- Business
- Valuence Merger Corp. I is a blank check company, or special purpose acquisition company (SPAC), whose principal business activity is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company focuses on privately held Asia-based targets developing breakthrough technology in life sciences and/or advancing platforms for sustainable technology; it operates without significant ongoing business operations prior to completing an initial business combination. Its securities, including units (VMCAU), Class A ordinary shares (VMCA), and redeemable warrants (VMCAW), trade on the Nasdaq Global Market. Valuence Merger Corp. I was incorporated in 2021 and maintains its headquarters in Orinda, California; it is backed by strategic partners including Crystal BioSciences, a South Korean venture capital firm investing in life sciences startups; Credian Partners, a South Korean private equity firm specializing in acquisitions, divestitures, recapitalizations, and growth equity; and Quantum Leaps Corp., a Japanese firm fostering cross-Asian collaborations in technology and capital. In recent developments, the company has pursued multiple one-month extensions of its business combination deadline, including approvals in September 2024 to October 2024, November 2024 to December 2024, and further extensions into 2025 up to a potential March 2026 limit, while depositing additional funds into its trust account to support ongoing efforts to identify and consummate a target merger. As of mid-2025, no specific acquisition target or business combination has been publicly announced, with the SPAC continuing to seek opportunities amid competitive market dynamics.